Active Filter(s):
Details:
JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation (SHM) antibody platform and subsequently developed by TESARO, Inc., now a part of GSK, under a collaboration agreement.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Approved Product Type: Large molecule
Recipient: AnaptysBio
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 17, 2021